The United Kingdom and the United States have hammered out a important bilateral deal that will keep zero duties on British medicine shipments entering the American market.
The Terms of the Pact
As part of the deal, the UK has pledged to raise funding on pharmaceuticals through the NHS. This commitment ensures that tariffs on these key products will be held at zero for a duration of three years.
This development comes after previous threats to hike duties on patented drug products, with potential rates mentioned up to double the cost.
"This agreement between the United Kingdom strengthens the global environment for innovative medicines and establishes long-overdue balance to U.S.–U.K. medicine commerce," an announcement declared.
Trade Impact
Drugs represent one of the the United Kingdom's largest goods shipped to the United States, which is by far the biggest destination for large UK drugmakers.
Statistics reveal that in the year prior to last September, the UK sold medicines valued at £11.1bn to the US. This figure made up nearly one-fifth of British export trade in that period.
"This deal secures work, stimulates funding and paves the way for the UK to establish itself as a global hub for medical research," the Business and Trade Secretary commented.
Key British Pledges
The pact includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to increase total NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at 15%. Previously, refunds topped 20%.
Broader Context
The pact comes amid a long-running dispute between the drug companies and the British authorities over medicine costs and NHS adoption.
This friction were exacerbated by assertions that American patients were charged significantly more for the same drugs than consumers in the Britain and the EU.
In recent months, several major drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the last ten years.